ROSGQ Rosetta Genomics Ltd (CE)

Rosetta Collaborative Study Profiling microRNAs Published in Clinical & Translational Oncology

Demonstrates microRNA Regulation of Epithelial Mesenchymal Transition, a Key Contributor to Metastases

PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Dec 10, 2013) - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that data from a collaborative study between Rosetta and a leading research team in the field of Cancer of Unknown Primary (CUP) at the University of Ioannina, were published online in Clinical & Translational Oncology in an article titled, "Insights into the epithelial mesenchymal transition phenotype in cancer of unknown primary from a global microRNA profiling study." The article can be accessed online at http://link.springer.com/article/10.1007%2Fs12094-013-1139-5 and is expected to be published in the print edition of Clinical & Translational Oncology.

The study examined the microRNA regulation of epithelial mesenchymal transition (EMT) and the acquisition of migratory, mesenchymal-like properties of epithelial cells in CUP. In the study, the global expression profile of 982 microRNAs were evaluated by means of microarray technology in 68 CUP cases that were immunohistochemically characterized as EMT-positive or EMT-negative. According to the study's lead author, Aikaterini Stoyianni, M.D., Ph.D. candidate, Medical School, University of Ioannina, Greece, "The study results showed the EMT-suppressive miR-203 and miR-200 family were consistently but non-significantly down regulated in CUP samples with the EMT phenotype."

"In view of the consistency of the observed levels of miR200 family expression by EMT status, more sensitive EMT-capturing technologies and larger CUP cohorts should be studied for further validation of these data," commented George Pentheroudakis, M.D., Ph.D., Assistant Professor of Oncology at the University of Ioannina, Greece and a co-author of the study.

"Metastasis constitutes the most common cause of death for cancer patients and EMT is a key contributing factor to that process," noted Dganit Bar, Chief Scientific Officer of Rosetta Genomics. "These data suggest that microRNAs may play an important role in EMT, which could have a direct effect on cancer metastases and illustrates the central role of microRNAs in cancer biology. Due to this central role, microRNAs are both interesting drug targets and excellent biomarkers."

"We are pleased with this new publication as it underscores the unfolding potential for microRNA technology in cancer therapeutics and as biomarkers for various cancer-related processes including EMT," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta. "Rosetta has what we believe to be one of the broadest intellectual property portfolios in the area of microRNA technology, and has 44 peer-reviewed publications to its credit which further demonstrates our leadership in this area as well as the robustness of our world class, microRNA platforms. We expect to leverage our IP and leading microRNA capabilities and platforms to advance these and other discoveries toward commercialization either through collaborations, partnerships and/or through our own internal development initiatives."

About Rosetta Cancer Testing Services Rosetta Cancer Tests are a series of microRNA-based diagnostic testing services offered by Rosetta Genomics. The Rosetta Cancer Origin Test™ can accurately identify the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP). Rosetta Mesothelioma Test™ diagnoses mesothelioma, a cancer connected to asbestos exposure. The Rosetta Lung Cancer Test™ accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. The Rosetta Kidney Cancer Test™ accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma. Rosetta's assays are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the Rosetta Cancer Origin Test™, 60,000 from the Rosetta Mesothelioma Test™, 65,000 from the Rosetta Kidney Cancer Test™ and 226,000 patients from the Rosetta Lung Cancer Test™. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.rosettagenomics.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation: The role that microRNAs may play in EMT, as well as the roll of microRNAs in cancer biology, any future study and validation of more sensitive EMT-capturing technologies and larger CUP cohorts, the potential for use of microRNA technology in cancer therapeutics, Rosetta's intellectual property portfolio in the area of microRNA technology. Rosetta leveraging its IP and leading microRNA capabilities to advance technologies toward commercialization either through collaborations, partnerships and/or through Rosetta internal development initiatives, and the possible role of microRNA's as drug targets constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact: Rosetta Genomics Ken Berlin President & CEO (609) 419-9000, ext. 1326 investors@rosettagenomics.com Investor Contacts: HA Anne Marie Fields (212) 838-3777 afields@lhai.com or Bruce Voss (310) 691-7100 bvoss@lhai.com